Drug intelligence / Profile preview

enalodustat

Development stage: Unknown
Lead developer: Japan Tobacco
Modality: Small Molecules
Administration: Oral

Overview

Enalodustat is an orally active small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH). By inhibiting the HIF-PH enzyme, enalodustat stabilizes HIF-α subunits, which then dimerize with HIF-β to form a transcription factor complex. This complex induces the expression of erythropoietin (EPO) and other genes involved in iron transport and erythropoiesis, effectively stimulating red blood cell production. Developed by Japan Tobacco and marketed by Torii Pharmaceutical, enalodustat (brand name Enaroy) was approved in Japan in 2020 for the treatment of anemia associated with chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patients. It is also being investigated for its potential benefits in heart failure patients with concomitant renal anemia.

Brand names: Enaroy
Other names: enalodustat sodium

Targets

PHD1 (Prolyl hydroxylase domain-containing protein 1)PHD3 (Prolyl hydroxylase domain-containing protein 3)EGLN1 (Prolyl hydroxylase domain-containing protein 2)

Beyond the preview

Go deeper on enalodustat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on enalodustat.

Explore the full profile